Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that acute telogen effluvium after COVID-19 typically began about 1.5 months post-infection and resolved sooner than typical cases, with most resolving in under two months.

This systematic review reports that acute telogen effluvium may occur as a stress-induced hair loss following COVID-19 recovery, with most patients experiencing hair regrowth over time.

This study found that COVID-19 infection is a frequent cause of acute telogen effluvium, leading to excessive hair loss within 2–3 months after infection.

A woman's sudden hair loss was linked to her previous COVID-19 infection.

This report describes a case of acute telogen effluvium in a 38-year-old woman following recovery from COVID-19.

This case report details two women with female pattern hair loss who experienced severe scalp allergic contact dermatitis from minoxidil, one due to the active ingredient and the other due to the vehicle.

This study found that severe diets, iron deficiency, and thyroid dysfunction are significant predictors of acute telogen effluvium's association with female androgenetic alopecia.

This study reports that a third of patients with SARS-CoV-2 infection developed acute telogen effluvium within three weeks, highlighting a notable pattern of early hair loss following COVID-19.

This study suggests that observing the acute telogen effluvium triad—frontal fringe, temporal recess, and occipital fringe—can aid in diagnosing telogen effluvium during resolution phases, despite challenges like negative pull tests.

This article reviews the Directory of Open Access Journals, an extensive global index of quality open access journals, and reports no new results.

This study reported that the tested hair lotion significantly reduced hair loss and accelerated recovery in women with acute telogen effluvium compared to a mild shampoo alone.

This study found that hair follicles on the anterior scalp may be more vulnerable to acute telogen effluvium than those on the occipital scalp.

This review discusses the mechanisms, causes, and treatment options for telogen effluvium, noting acute cases often resolve by addressing causative factors, while chronic forms remain challenging to treat; recent causes include post-hair transplantation, vitamin D deficiency, and COVID-19.

In this study, women with acute telogen effluvium taking the Hair’InsideTM supplement for 84 days showed significant improvements in hair regrowth, shedding, brightness, and volume compared to placebo, with no reported adverse effects.

In this clinical study, the researchers found that a standardized wheat polar lipid complex, in both oil and powder form, significantly reduced hair shedding and improved hair growth in 99 women with acute telogen effluvium over 56 to 84 days.

In this descriptive cross-sectional study conducted at a Karachi hospital, researchers found a high prevalence of Telogen Effluvium in female COVID-19 survivors, particularly those with diabetes, and noted that dietary supplementation may be linked to reduced hair loss severity post-infection.

In this review, researchers reported that post-COVID-19 syndrome may lead to significant sequelae like hair loss, potentially due to acute telogen effluvium, affecting around 20% of patients and impacting their quality of life, though specific studies on this relationship are lacking.

This study found that 72% of patients who recovered from COVID-19 during the second wave reported experiencing significant hair loss, characteristic of telogen effluvium.

This review summarizes findings on hair loss caused by COVID-19, noting that Telogen Effluvium frequently occurs in female patients 63 days post-infection, often in those with mild to moderate cases and certain comorbidities.

This study found that 74.6% of COVID-19 patients in Prayagraj experienced telogen effluvium hair loss, predominantly affecting females.

In this study, researchers observed a high prevalence of ferritin and vitamin D deficiency in women with acute telogen effluvium, highlighting the importance of laboratory screening for these deficiencies, while also noting a correlation between ferritin levels and hair loss severity.

This case report highlights a rare instance of post-COVID-19 telogen effluvium in a 6-year-old girl, underscoring its psychological impact and self-limiting nature.

This study found that among female patients with acute telogen effluvium, 83.7% reported either partial or complete resolution of hair shedding after three months of treatment including vitamin E and zinc supplements.

Treating post-COVID hair loss leads to full recovery, while not treating it often results in ongoing symptoms.

This review discusses the phases of the human hair cycle and highlights the importance of identifying factors that disturb it, but reports no new clinical findings.

This case report highlights a patient who developed acute hepatitis after consuming an oral green tea derivative for hair loss, with recovery following the cessation of the product.

This study observed that both SARS-CoV-2 and other acute respiratory infections are linked to a wide range of long-term symptoms, highlighting the need to investigate post-acute sequelae beyond COVID-19.

This review discusses the phases of the human hair cycle, the factors affecting telogen effluvium, and the need for investigation if persistent hair shedding occurs, but reports no new clinical results.